Commentary on 'designing phase II studies in cancer with time-to-event endpoints'.
Case
Doug
D
Department of Biostatistical Sciences, Division of Public Health Sciences, Wake Forest University School of Medicine, North Carolina, USA. dcase@wfubmc.edu
Morgan
Tim
T
D017322:Clinical Trials, Phase II as Topic / Q000379:methods*; D023381:Endpoint Determination; D006801:Humans; D015233:Models, Statistical; D009369:Neoplasms / Q000628:therapy*; D012107:Research Design